Halozyme Therapeutics, Inc.
HALO
$63.65
-$1.48-2.27%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -141.59M | 175.23M | 165.16M | 118.10M | 137.01M |
| Total Depreciation and Amortization | 26.68M | 20.42M | 20.50M | 20.45M | 20.42M |
| Total Amortization of Deferred Charges | 1.95M | 1.86M | 1.85M | 1.85M | 1.84M |
| Total Other Non-Cash Items | 341.42M | 39.37M | 4.22M | 6.36M | -6.17M |
| Change in Net Operating Assets | -9.43M | -58.28M | -92.02M | 7.47M | 25.37M |
| Cash from Operations | 219.03M | 178.60M | 99.71M | 154.22M | 178.47M |
| Capital Expenditure | -1.43M | -3.03M | -1.56M | -950.00K | -3.05M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -725.97M | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -14.40M | 204.64M | 86.35M | -89.47M | 32.53M |
| Cash from Investing | -741.79M | 201.61M | 84.79M | -90.42M | 29.48M |
| Total Debt Issued | 1.47B | -- | -- | -- | -- |
| Total Debt Repaid | -845.43M | -- | -- | -- | -- |
| Issuance of Common Stock | 4.15M | 16.48M | 1.20M | -- | 3.59M |
| Repurchase of Common Stock | 0.00 | -38.88M | -300.17M | -3.32M | -250.00M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -389.21M | -- | -- | -- | -- |
| Cash from Financing | 239.52M | -22.40M | -298.97M | -3.32M | -246.42M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -283.24M | 357.80M | -114.47M | 60.48M | -38.47M |